Results 51 to 60 of about 15,728 (206)

Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication

Haematologica, 2015
In patients with acute coronary syndrome, dual antiplatelet therapy with aspirin and a P2Y12 inhibitor like prasugrel is prescribed for one year. Here, we investigated how the hemostatic function of platelets recovers after discontinuation of prasugrel ...
Constance C. F. M. J. Baaten, Leo F. Veenstra, Rick Wetzels, Johanna P. van Geffen, Frauke Swieringa, Susanne M. de Witt, Yvonne M. C. Henskens, Harry Crijns, Sven Nylander, J. J. J. van Giezen, Johan W. M. Heemskerk, Paola E. J. van der Meijden   +11 more
doaj   +1 more source

Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis

BMC Cardiovascular Disorders, 2020
Background This meta-analysis aimed to compare the effects of prasugrel and ticagrelor on high (HTPR) and low on-treatment platelet reactivity (LTPR) in patients with acute coronary syndrome (ACS).
Mingxiang Wen, Yaqi Li, Xiang Qu, Yanyan Zhu, Lingfang Tian, Zhongqin Shen, Xiulin Yang, Xianqing Shi   +7 more
doaj   +1 more source

Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study

Marshall Journal of Medicine, 2019
Prasugrel is a thienopyridine that was approved by the US Food and Drug Administration (FDA) in combination with aspirin for the reduction of thrombotic events as well as stent thrombosis in patients with ACS who undergo PCI.
Ahmed Amro, Kanaan Mansoor, Mohammad Amro, Amal Sobeih, Obadah Aqtash, Hisham Hirzallah, Alaa Gabi , Madhulika Urella, Waseem Ahmed , Sandra Shenouda, Rameez Sayyed   +10 more
doaj   +1 more source

Variability of response on prophylactic prasugrel for endovascular treatment of intracranial aneurysms: Clinical implications.

PLoS ONE, 2023
Background and purposeProphylactic prasugrel for endovascular treatment of intracranial aneurysms has been introduced and increased, but HTPR (high on-treatment platelet reactivity) or LTPR (low on-treatment platelet reactivity) of prasugrel is not ...
Noah Hong, Seung Bin Kim, Hee-Jin Yang, Young-Je Son   +3 more
doaj   +1 more source

Ticagrelor vs Prasugrel for Acute Coronary Syndrome in Routine Care

JAMA Network Open
This cohort study compares the cardiovascular and major bleeding outcomes of prasugrel vs ticagrelor among new users undergoing invasive treatment for acute coronary syndrome.
N. Krüger, J. Krefting, Thorsten Kessler, R. Schmieder, F. Starnecker, A. Dutsch, C. Graesser, U. Meyer-Lindemann, T. Storz, Irina Pugach, C. Friess, Zhifen Chen, Dario Bongiovanni, I. Manea, T. Dreischulte, F. Offenborn, P. Krase, H. Sager, J. Wiebe, S. Kufner, E. Xhepa, M. Joner, T. Trenkwalder, Ulrich Gueldener, Adnan Kastrati, S. Cassese, H. Schunkert, M. von Scheidt   +27 more
semanticscholar   +1 more source

P‐CAB vs. PPI for Upper Gastrointestinal Bleeding Prevention in Patients With Atherothrombotic Disease on Antithrombotic Therapy: A CDM Cohort Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In patients with atherothrombotic disease on antithrombotic therapy, P‐CABs demonstrated a significantly superior protective effect against clinically significant upper GI haemorrhage compared to PPIs (aHR 0.22; p = 0.016). This real‐world study highlights P‐CABs as a more potent gastroprotective strategy for high‐risk populations requiring intensive ...
Min Joo Yoon, Soyoung Lee, Hye‐Kyung Jung, Min‐ho Kim, Suna Yu, Eui Sun Jeong, Chung Hyun Tae   +6 more
wiley   +1 more source

Thrombocytosis and the generation of platelet‐derived microparticles in the pathophysiology of sickle cell disease

British Journal of Haematology, EarlyView.
Thrombocytosis is associated with an increased production of platelet‐derived microparticles from activated platelets, which contribute to vaso‐occlusion in sickle cell disease by perpetuating the cycle of inflammation, procoagulant state and endothelial dysfunction.
Giao N. Lê, Anna Dillon, Owen P. Smith, Corrina McMahon   +3 more
wiley   +1 more source

A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease

Journal of Hematology & Oncology, 2013
Background Platelet activation has been implicated in the pathogenesis of sickle cell disease (SCD) suggesting antiplatelet agents may be therapeutic. To evaluate the safety of prasugrel, a thienopyridine antiplatelet agent, in adult patients with SCD ...
Wun Ted, Soulieres Denis, Frelinger Andrew L, Krishnamurti Lakshmanan, Novelli Enrico M, Kutlar Abdullah, Ataga Kenneth I, Knupp Charles L, McMahon Lillian E, Strouse John J, Zhou Chunmei, Heath Lori E, Nwachuku Chuke E, Jakubowski Joseph A, Riesmeyer Jeffrey S, Winters Kenneth J   +15 more
doaj   +1 more source

Effects of Clopidogrel, Prasugrel and Ticagrelor on Microvascular Function and Platelet Reactivity in Patients With Acute Coronary Syndrome Undergoing Coronary Artery Stenting. A Randomized, Blinded, Parallel Group Trial

Frontiers in Cardiovascular Medicine, 2021
Aims: In this pre-specified analysis of the “endothelium, stent and antiplatelet therapy” study, we investigate the impact of antiplatelet therapies on microvascular function in patients undergoing stenting for an acute coronary syndrome.Methods and ...
Boris Schnorbus, Boris Schnorbus, Kerstin Jurk, Karl J. Lackner, Caroline Welk, Thomas Münzel, Tommaso Gori, Tommaso Gori   +7 more
doaj   +1 more source

The potential for biased signalling in the P2Y receptor family of GPCRs

British Journal of Pharmacology, EarlyView.
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk, Simon Pitchford, Graham Ladds   +2 more
wiley   +1 more source